Background: Recombinant C1 inhibitor (rhC1INH) is a novel therapeutic option for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). The amino acid sequence of rhC1INH is identical to that of endogenous C1INH. However, any recombinant protein may elicit antibodies against the protein and/or host related impurities (HRI). Clinical consequences of these antibodies can theoretically range from no clinical symptoms to allergic reactions and reduced C1INH activity due to neutralizing antibodies. Objective: To analyze the immuno-safety of rhC1INH in symptomatic patients with HAE. Methods: Plasma samples were collected pre-treatment and 22 and 90 days post-treatment of an acute angioedema attack. Plasma samples were tested for the presence of antibodies against plasma-derived C1INH and rhC1INH using 6 different, validated enzyme-linked immunosorbent assays (ELISAs), to detect IgM, IgG and IgA antibodies against plasma-derived C1INH or rhC1INH. Antibodies against HRI in plasma samples were measured in an ELISA testing for all antibody classes. Plasma samples from normal healthy controls and HAE patients, never exposed to rhC1INH, were used to estimate cut off levels of the assays. Plasma samples with antibody levels above the cut-off level in the screening assays were tested in confirmatory displacement assay in case of anti-HRI antibodies and in an assay for neutralizing antibodies in case of antibodies against C1INH. Results: Data from 155 symptomatic HAE patients having received a total of 424 administrations of rhC1INH were analyzed. The frequency of anti-C1INH antibody levels above the assay cut-off was low and similar in pre-and post-exposure samples (1.7 and 1.8%, respectively). Results above the assay cut-off were sporadic and transient. Occurrence of anti-C1INH antibodies did not correlate with repeated treatment or time since last treatment. No neutralizing antibodies were detected. A total of 5/155 (3%) rhC1INH-treated patients had confirmed anti-HRI antibodies; these included 1 patient with presence of anti-HRI antibodies prior to exposure to rhC1INH. The presence of anti-C1INH and anti-HRI antibodies was not associated with clinical symptoms. The presence of anti-C1INH antibodies did not affect clinical efficacy. Conclusions: rhC1INH used for the treatment of acute HAE attacks has a low potential to induce antibodies and has a reassuring immuno-safety profile. Objective: To review the integrated efficacy data of rhC1INH for treatment of acute HAE attacks. Methods: Efficacy was assessed using patient-reported HAE-specific visual analog scales. The primary endpoint was time to onset of relief of symptoms (VAS decrease $20 mm), and the secondary efficacy endpoint was time to minimal symptoms (VAS ,20 mm at all locations). Other endpoints included clinical response (relief achieved within 4 hours) and relapse (recurrence of symptoms within 24 hours following initial improvement). Subgroup analyses by attack location were also performed. Results: The dataset included 141 HAE patients treated for 403 attacks. Median times to the onset of symptom relief for attacks treated with 100 U/ kg, 50 U/kg and 2100 U rhC1INH were 66, 60, and 61 minutes, respectively, compared to 495 minutes in the placebo-treated group. Median times for time to minimal symptoms were 266, 240 and 241 minutes for the 100 U/kg, 50 U/ kg, and 2100 U rhC1INH-treated attacks respectively compared to 1210 minutes for the placebo-treated attacks. High clinical response rates were observed for the rhC1INH-treated groups (93, 96 and 88% for the 100 U/kg, 50U/kg, and 2100 U respectively) compared to the placebo group (41%). None of the rhC1INH-treated attacks relapsed. Subgroup analysis by attack location showed that abdominal attacks had the fastest median time to onset of symptom relief (50, 36 and 60 minutes for 100 U/kg, 50 U/kg and 2100 U doses respectively), followed by oro-facial-pharyngeal-laryngeal attacks (70, 65 and 120 minutes), and peripheral attacks (75, 84 and 121 minutes). No drug-related serious adverse events or hypersensitivity reactions were observed. Conclusions: RhC1INH has demonstrated efficacy for the treatment of repeated HAE attacks for all doses tested (100 U/kg, 50 U/kg and 2100 U). Controlled studies did not show additional benefit with doses greater than 50 U/kg. RhC1INH was generally safe and well tolerated. 
. Scienze Cliniche "Luigi Sacco", Università di Milano, Ospedale L. Sacco, Milano, Italy; 9 Medicine, University of California, San Diego, La Jolla, CA. Background: Recombinant human C1 Inhibitor (rhC1INH) has been approved in Europe for the treatment of acute hereditary angioedema attacks. The efficacy of rhC1INH was demonstrated in 2 randomized-controlled trials. Open-label extension studies, where patients could be treated for subsequent HAE attacks, demonstrated continued efficacy for repeated rhC1INH treatments. Objective: To review the integrated efficacy data of rhC1INH for treatment of acute HAE attacks. Methods: Efficacy was assessed using patient-reported HAE-specific visual analog scales. The primary endpoint was time to onset of relief of symptoms (VAS decrease $20 mm), and the secondary efficacy endpoint was time to minimal symptoms (VAS ,20 mm at all locations). Other endpoints included clinical response (relief achieved within 4 hours) and relapse (recurrence of symptoms within 24 hours following initial improvement). Subgroup analyses by attack location were also performed. Results: The dataset included 141 HAE patients treated for 403 attacks. Median times to the onset of symptom relief for attacks treated with 100 U/ kg, 50 U/kg and 2100 U rhC1INH were 66, 60, and 61 minutes, respectively, compared to 495 minutes in the placebo-treated group. Median times for time to minimal symptoms were 266, 240 and 241 minutes for the 100 U/kg, 50 U/ kg, and 2100 U rhC1INH-treated attacks respectively compared to 1210 minutes for the placebo-treated attacks. High clinical response rates were observed for the rhC1INH-treated groups (93, 96 and 88% for the 100 U/kg, 50U/kg, and 2100 U respectively) compared to the placebo group (41%). None of the rhC1INH-treated attacks relapsed. Subgroup analysis by attack location showed that abdominal attacks had the fastest median time to onset of symptom relief (50, 36 and 60 minutes for 100 U/kg, 50 U/kg and 2100 U doses respectively), followed by oro-facial-pharyngeal-laryngeal attacks (70, 65 and 120 minutes), and peripheral attacks (75, 84 and 121 minutes) . No drug-related serious adverse events or hypersensitivity reactions were observed. Conclusions: RhC1INH has demonstrated efficacy for the treatment of repeated HAE attacks for all doses tested (100 U/kg, 50 U/kg and 2100 U). Controlled studies did not show additional benefit with doses greater than 50 U/kg. RhC1INH was generally safe and well tolerated. Icatibant, a selective bradykinin b2 receptor antagonist, licensed for use in acute attacks of hereditary angioedema could be also effective in treating other forms of angioedema. We report a patient with idiopathic angioedema who was successfully treated with icatibant. Methods: A 77-year-old man with a history of arterial hypertension currently treated with hydrochlorothiazide and type II diabetes under insulin treatment. He had suffered from recurrent angioedema attacks located on his tongue without urticaria during the last 7 years. Serum levels of C1-INH, C4 and C1q and C1-INH activity were normal. In spite of cessation of treatment with ACE inhibitors and RAAS-blockers (he had been treated with enalapril and losartan previously) he continued with the angioedema attacks. As no cause of angioedema could be identified and the angioedema did not response to antihistamines, the patient was diagnosed of idiopathic nonhistaminergic angioedema. In one of the episodes he was admitted at the emergency room with a swollen tongue. The edema gradually progressed in spite of the treatment with antihistamines, corticosteroids and epinephrine. Tracheotomy was considered due to the severity of the angioedema that began to cause airway compromise. After consulting the Allergy Unit, treatment with icatibant was administered.
Results: Approximately 30 minutes after the subcutaneous administration of icatibant 30 mg the symptoms improved and the angioedema resolved completely within 6 hours. The only adverse effect following the icatibant administration was pain localized in the injection site. After 5 months the patient suffered a similar attack that was also successfully treated with icatibant sc. Conclusions: Icatibant administered subcutaneously provided an effective and well-tolerated treatment option for acute angioedema attacks in a patient with idiopathic nonhistaminergic angioedema. This form of angioedema could have a pathogenic mechanism similar to the bradikinin mediated angioedema. We suggest the use of icatibant in the treatment of severe attacks of angioedema in patients that do not response to antihistamines, corticosteroids and epinephrine. Background: Although history taking is primary method in the diagnosis of bee venom allergy, serum specific IgE detection is critical to identify causative bee and assess the effect of immunotherapy. Component-resolved diagnosis (CRD) in allergy has been used for its high sensitivity and specificity in many allergy diseases caused by food, cat, birch, and grass pollens. The purposes of this study are to evaluate diagnostic value of serum specific IgE to 3 bee venom component allergens and observe the changes of allergen specific IgE during bee venom immunotherapy. Methods: Fifty-six bee venom anaphylaxis patients receiving bee venom immunotherapy were recruited from Ajou University Hospital. Clinical manifestations and serum specific IgE levels to bee venoms and component allergen (rApi m1 of Apidae, rVes v5 and rPol d5 of Vespidae) measured by using ImmunoCAP (Phadia, Sweden) were analyzed retrospectively. Results: Thirty-five (62.5%) patients were male and 33 (73.3%) were atopics. Their mean age was 44.9 6 13.8 years ranged from 11 to 73 years. Local reactions were found in 13 (23.2%) patients, while systemic reactions, in 43 (76.8%) patients. The most frequent manifestation was anaphylaxis which were severe (37.5%) and moderate (39.3%) manifestations followed by urticaria and angioedema. Yellow Jacket (80.8%) was the most prevalent bee followed by yellow hornet, white faced hornet, honey bee and paper wasp at the time of diagnosis with concurrent sensitization in both Apidae and Vespidae at 70.9% patients. The positive predictive value (PPV) of serum specific IgE levels to rVes v5 and rPol d5 were 85.7 and 87.5%, and they significantly correlated with conventional serum specific IgE level (r ¼ 0.762 and r ¼ 0.757, respectively), however, PPV of rApi m1 was only 34.8% at the time of initial diagnosis. After 3 years of bee venom immunotherapy, all kinds of bee venom specific IgE levels tended to decline compared to those collected before allergen immunotherapy, especially in component specific IgE to Vespidae. Conclusions: Yellow jacket sting and male gender may be risk factors for bee venom allergy in Korea. Component allergen specific IgE to Vespidae, not Apidae had a diagnostic and monitoring value comparable to conventional specific IgE in bee venom allergy.
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